MedTrace Logo

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

NCT04522544 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2026-02-18

No results posted yet for this study

Summary

A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with Y-90 SIRT for intermediate stage HCC

Conditions

  • Hepatocellular Carcinoma Non-resectable
  • HCC

Interventions

DRUG

Tremelimumab

300 mg Tremelimumab C1D1

DRUG

Durvalumab

1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles)

PROCEDURE

Y-90 SIRT

Locoregional therapy will be performed as a standard-of-care procedure

PROCEDURE

DEB-TACE

Locoregional therapy will be performed as a standard-of-care procedure

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Hannover Medical School

    collaborator OTHER

  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

    lead OTHER

Principal Investigators

  • Salah-Eddin Al-Batran, Prof. Dr. · Frankfurter Institut für Klinische Krebsforschung IKF GmbH

  • Arndt Vogel, Prof. Dr. · Hannover Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2027-07-31
Completion
2027-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04522544 on ClinicalTrials.gov